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MEDICAL MARIJUANA 
LEGISLATION: WHAT WE KNOW—
AND DON’T 
LINDA SIMONI-WASTILA 
FRANCIS B. PALUMBO 
I.  INTRODUCTION 
The use of marijuana as a medicinal agent available to individuals suffering 
from pain, glaucoma, wasting syndromes associated with HIV and AIDS, nausea 
from chemotherapy, and a host of other medical conditions and symptoms has 
become more widely accepted.1 Over the past decade, eighteen states and the 
District of Columbia have adopted medical marijuana legislation (MML) that 
allows citizens to register, cultivate, and/or otherwise procure marijuana for 
personal medical use.2 Additionally, the Maryland Legislature has passed a bill 
that, if signed by the Governor, would provide for distribution of medical 
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 1. See, e.g., JANET E. JOY ET AL., MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE 22–
24 (1999) (listing different disorders treated with marijuana at two California Cannabis Cultivators 
Clubs); Sunil K. Aggarwal et al., Medicinal Use of Cannabis in the United States: Historical 
Perspectives, Current Trends, and Future Directions, 5 J. OPIOID MGMT. 153, 156 (2009) (explaining 
that studies show the therapeutic potential of cannabinoids). 
 2. Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, 
Hawaii, Maine, Massachusetts, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode 
Island, Vermont, and Washington have all adopted MML. ALASKA STAT. § 17.37 (2010); ARIZ. REV. 
STAT. ANN. §§ 36-2801–19 (Supp. 2012); CAL. HEALTH & SAFETY CODE § 11362.5 (West 2007), § 
11362.7–.9; COLO. CONST. art. XVIII, § 14; COLO. REV. STAT. ANN. §§ 12-43.3-101–106 (West 2012), 
§ 18-18-406.3 (West 2012), § 25-1.5-106 (West 2012); 2012 Conn. Acts 55 (Reg. Sess.); DEL. CODE 
ANN. tit. 16, §§ 4901a–4926a (2011); D.C. CODE §§ 7-1671 (Supp. 2012); HAW. REV. STAT. ANN. §§ 
329-121–128 (LexisNexis 2008 & Supp. 2011); ME. REV. STAT. ANN. tit. 22, §§ 2421–2430-B (Supp. 
2011); 2012 Mass. Legis. Serv. 369 (West); MICH. COMP. LAWS ANN. §§ 333.26421–.26430 (West 
Supp. 2012); MONT. CODE ANN. §§ 50-46-301–344 (2011); NEV. CONST. art IV, § 38; NEV. REV. STAT. 
ANN. §§ 453A.010–.810 (LexisNexis Supp. 2011); N.J. STAT. ANN. §§ 24:6I-1–16 (West Supp. 2012); 
N.M. STAT. ANN. §§ 26-2B-1–7 (LexisNexis Supp. 2011); OR. REV. STAT. ANN. §§ 475.300–.346 
(2011); R.I. GEN. LAWS §§ 21-28.6-1–12 (2011); VT. STAT. ANN. tit. 18, §§ 4472–74l (LexisNexis 
Supp. 2012); WASH. REV. CODE ANN. §§ 69.51A.005–.903 (West 2012).  
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marijuana through academic medical centers,3 The popularity of medical marijuana 
legislation continues, with an additional eleven states considering ballot initiatives.4  
In response to the widespread acceptance of marijuana as a medical aide and 
the subsequent adoption of MML, a 2009 American Medical Association Council 
on Science and Public Health Report noted that the patchwork of state-based 
systems that have been established for medical marijuana is ―woefully 
inadequate‖ to establish even rudimentary safeguards including patient 
information handouts that normally would be applied to the appropriate clinical 
use of psychoactive substances.5 The unwieldy patchwork of varying MML is 
negatively compounded by the lack of research on both utilization and health 
outcomes, as well as patterns or emerging trends in state with such legislation or 
regulations.6 Even basic information, such as the number of patients who use 
marijuana in states that have removed state-level penalties, has not been clearly 
established.7 To date, research relating to medical marijuana has focused on the 
historical use of cannabis as medicine,8 current scientific and medical 
understanding of marijuana‘s role in human health,9 and the safety and efficacy 
of medical marijuana.10 Even clinical research is hampered by the reluctance of 
federal funders to sponsor such research, as well as the difficulty in obtaining 
government-approved strains for research purposes.11 From a policy perspective, 
there remains a paucity of research evaluating the efficacy of decriminaliza tion 
 
 3. H.B. 1101, 433rd Leg., 1st Sess. (Md. 2013). 
 4. PROCON.ORG, 11 States with Pending Legislation to Legalize Medical Marijuana. 
http://medicalmarijuana.procon.org/view.resource.php?resourceID=002481 (last modified March 6, 
2013) (Noting that as of March 2013, Alabama, Florida, Illinois, Iowa, Kansas, Kentucky, Maryland, 
Missouri, New Hampshire, New York, and West Virginia all have pending legislation proposing to 
legalize Medical Marijuana). 
 5. COUNCIL ON SCI. & PUB. HEALTH, AM. MED. ASS‘N, REPORT NO. 3, USE OF CANNABIS FOR 
MEDICINAL PURPOSES 15 (2009). 
 6. Id.  
 7. Id. at 6. 
 8. See JOY ET AL., supra note 1, at 19 (noting marijuana‘s use as an herbal remedy before the 20th 
century); Aggarwal et al., supra note 1, at 157 (calling the medicinal use of marijuana a ―rediscovery‖ 
rather than ―a novel medical practice‖). 
 9. See AM. COLL. OF PHYSICIANS, SUPPORTING RESEARCH INTO THE THERAPEUTIC ROLE OF 
MARIJUANA 5, 9 (2008) (noting that side effects, methods of administration, and the availability of 
alternatives are all factors used to assess the medicinal value of marijuana); see also Mohamed Ben 
Amar, Cannabinoids in Medicine: A Review of their Therapeutic Potential, 105 J. 
ETHNOPHARMACOLOGY 1, 3 (2006) (describing various adverse effects of medical marijuana on certain 
illnesses). 
 10. See Sean M. Bagshaw & Neil A. Hagen, Medical Efficacy of Cannabinoids and Marijuana: A 
Comprehensive Review of the Literature, 18 J. PALLIATIVE CARE 111, 111 (2002) (noting that scientific 
data on the safety and efficacy of medical marijuana is currently ―inconclusive‖); Tongtong Wang et al., 
Adverse Effects of Medical Cannabinoids: A Systematic Review, 178 CAN. MED. ASS‘N J. 1669, 1671 
(2008) (stating that published randomized controlled trials suggest the efficacy of medical marijuana). 
 11. See Gardiner Harris, Researchers Find Study of Medical Marijuana Discouraged, N.Y. TIMES, 
Jan. 19, 2010, at A14 (describing how the federal government has stalled efforts to conduct marijuana 
research). 
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efforts in states and other jurisdictions.12 Indeed, the general lack of knowledge 
of the impact of MML on use and consequences presents a critical barrier to 
designing state laws and regulations optimal for balancing treatment with 
desired social and public health outcomes. The purpose of this paper is twofold: 
1) to review the state of knowledge regarding key policy and legal aspects of 
MML;13 and 2) to offer potential frameworks for implementing and/or 
evaluating MML.14 In Part II, the current knowledge, or lack thereof, of 
important components of health outcomes and policies is discussed. These key 
knowledge gaps exist in a) social and health outcomes,15 b) means of data 
collection,16 c) medical boards‘ reaction to MML,17 and d) dispensary models 
and their successes).18 In Part III, we address potential models for addressing 
these gaps and implementing solutions. 
II.  MEDICAL MARIJUANA AND STATE LEGISLATION:  
WHAT WE KNOW AND WHAT WE DO NOT 
A.  Little research has studied differences in social and public health outcomes 
based on variations in state and jurisdictional Medical Marijuana Legislation 
Despite the growing adoption of MML, little is known about the influence 
of MML on consumption of marijuana, consumption of other controlled substances 
or alcohol, and consequent health outcomes. The few studies conducted to date 
present mixed and/or inconclusive findings, with some analyses finding MML 
increases recreational demand19 and others noting inconclusive evidence of such an 
effect.20 Some organizations argue that as medical marijuana becomes more 
 
 12. See Diane E. Hoffmann & Ellen Weber, Medical Marijuana and the Law, 362 NEW ENG. J. 
MED. 1453, 1456 (2010) (citing a lack of research as contributing to a lack of consistency in state 
medical marijuana laws). 
 13. See infra Part II. 
 14. See infra Part III. 
 15. See infra Part II.A. 
 16. See infra Part II.B. 
 17. See infra Part II.C. 
 18. See infra Part II.D. 
 19. See Jerald G. Bachman et al., Explaining Recent Increases in Students’ Marijuana Use: Impacts 
of Perceived Risks and Disapproval, 1976 through 1996, 88 AM. J. PUB. HEALTH 887, 889 (1998) 
(acknowledging that recent increases in marijuana use may be attributable to declines in disapproval and 
perceptions of potential risk); Rosalie Liccardo Pacula et al., Marijuana and Youth, in RISKY BEHAVIOR 
AMONG YOUTHS: AN ECONOMIC ANALYSIS 271, 274–75 (Jonathan Gruber ed., 2001) (offering several 
explanations for fluctuations in recreational demand of marijuana such as perceived harm and marijuana 
availability).  
 20. See Dennis M. Gorman & J. Charles Huber Jr., Do Medical Cannabis Laws Encourage 
Cannabis Use?, 18 INT‘L J. DRUG POL‘Y 160, 164 , 166 (2007) (finding no affirmative evidence that 
medical marijuana laws increase use of the drug); D. MARK ANDERSON & DANIEL I. REES, INST. FOR 
THE STUDY OF LABOR, DISCUSSION PAPER NO. 6112, MEDICAL MARIJUANA LAWS, TRAFFIC 
FATALITIES, AND ALCOHOL CONSUMPTION 6 (2011) (explaining that MML does not necessarily 
increase marijuana use, but may convert illicit users to becoming card-carrying patients). 
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normative, the reduction in perceived risk will spill over into the use of recreational 
marijuana.21 Indeed, the proportion of youth aged twelve to seventeen who 
perceived great risk of smoking marijuana once a week declined from 54.6% in 
2007 to 44.8% in 2011.22 A recent study using the 1999–2008 National Survey on 
Drug Use and Health (NSDUH) found MML passage associated with decreased 
perceived risk of marijuana‘s abuse potential.23  
The effect of marijuana on driving functions is unclear. Marijuana has been 
associated with impaired driving functions,24 but there also is evidence that such 
impairments do not lead to increased risk of collision.25 Although no evidence links 
the use of medical marijuana to impaired driving, a small body of literature 
suggests states with MML experience reductions in alcohol use and, consequently, 
alcohol-related fatalities, because increased use of medical and illicit marijuana 
serve as alcohol substitutes.26 That is, while alcohol has a well-accepted negative 
impact on driving function, marijuana‘s impact remains less clear. Indeed, analysis 
of Fatal Accident Reporting System (FARS) data suggests states with MML have 
experienced an 8.7% reduction in total fatal accidents and a 12.0% reduction in 
alcohol-related fatalities.27 The authors surmise their findings are due to: 1) 
increased use of marijuana (medical and illicit) in MML states (i.e., the substitution 
effect);28 2) reduced consumption of alcohol by marijuana users;29 and 3) an 
increased tendency of marijuana users to use the substance in the privacy of their 
homes, thereby reducing the risk of fatalities by reducing their exposure to 
impaired driving.30  
 
 21. See Effects of Medical Marijuana Legalization, COMMUNITY ANTI-DRUG COALITIONS AM., 1, 
http://www.cadca.org/files/policy_priorities/effectsmedicalmarijuana.pdf (last visited Apr. 1, 2013) 
(arguing that legalization of medical marijuana leads to decreases in perceived harm and increases in 
drug use). 
 22. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH & HUMAN 
SERVS., RESULTS FROM THE 2011 NATIONAL SURVEY ON DRUG USE AND HEALTH 5 (2012). 
 23. See ANDERSON & REES, supra note 20, at 9 (finding that medical marijuana legalization in 
Vermont and Rhode Island led to increased use among youth between eighteen and twenty-five years 
old in those states). 
 24. See generally R. Andrew Sewell et al., The Effect of Cannabis Compared with Alcohol on 
Driving, 18 AM. J. ON ADDICTIONS 185, 187 (2009).  
 25. See id. at 186; Erin Kelly et al., A Review of Drug Use and Driving: Epidemiology, Impairment, 
Risk Factors and Risk Perceptions, 23 DRUG & ALCOHOL REV. 319, 326 (2004). 
 26. See ANDERSON & REES, supra note 20, at 6 (citing a study concluding that marijuana and 
alcohol are substitutes, and another finding they were compliments). See generally Frank J. Chaloupka 
& Adit Laixuthai, Do Youths Substitute Alcohol and Marijuana? Some Economic Evidence, 23 E. ECON. 
J. 253 (2011) (discussing the effects of marijuana legislation on rates of youth alcohol abuse); John 
DiNardo & Thomas Lemieux, Alcohol, Marijuana, and American Youth: The Unintended Consequences 
of Government Regulation, 20 J. HEALTH ECON. 991, 1005 (2001) (finding that marijuana and alcohol 
are substitutes). 
 27. ANDERSON & REES, supra note 20, at 13–14. 
 28. Id. at 13. 
 29. Id. at 42 tbl.14 (illustrating a decrease in alcohol sales after legalization of medical marijuana). 
 30. Id. at 21. 
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B.  Data Limitations 
Evaluation of MML is hampered mostly by lack of data. There is no single 
available dataset that allows thorough examination of medical marijuana legislation 
and its influence on social and public health outcomes.31 Indeed, there are no data 
routinely collected on medical marijuana use across the nation or within states with 
MML.32 An ideal database would allow analyses of medical marijuana policy on 
medical, social, criminal, and public health-relevant outcomes at the individual 
level; however, due to privacy and cost constraints, such person-level data are 
prohibitively expensive to collect and analyze.33  
Because medical marijuana is not reimbursable under public or private 
insurance programs, administrative health claims data are useless.34 Data collected 
by law enforcement do not discriminate between marijuana used for medicinal or 
recreational purposes.35 Similarly, data collected in national surveys, such as the 
NSDUH and Monitoring the Future, only capture information on marijuana use and 
perceptions or risk, but not the reason for use.36 Thus, researchers cannot currently 
determine the prevalence of medical marijuana use for medical indications, nor 
examine the efficacy of medical marijuana and its impact on important public 
health and economic outcomes.37 
 
 31. See id. at 20. 
 32. See id. at 7–8 (discussing drawbacks to available data on marijuana use in states, including 
states that have passed MML). 
 33. See Lisa N. Pealer et al., The Feasibility of a Web-Based Surveillance System to Collect Health 
Risk Behavior Data from College Students, 28 HEALTH EDUC. & BEHAV. 547, 548 (discussing the 
difficulties methodological problems posed by traditional personal survey methods). 
 34. See Jeremy Smerd, Marijuana Reimbursement Claims Highlight How Pot Could be Gold for 
Employers, WORKFORCE (Sept. 7, 2011), http://www.workforce.com/article/20090714/NEWS02/307 
149995/marijuana-reimbursement-claims-highlight-how-pot-could-be-gold-for-employers# (noting that 
health insurance companies do not reimburse patients for drugs, such as medical marijuana, that are not 
FDA-approved). 
 35. See, e.g., FED. BUREAU OF INVESTIGATION, U.S. DEP‘T OF JUSTICE, Arrests, CRIME IN THE 
UNITED STATES, http://www.fbi.gov/about-us/cjis/ucr/crime-in-the-u.s/2010/crime-in-the-u.s.-
2010/persons-arrested (follow ―Download Arrest Table Excel‖ hyperlink) (last visited Apr. 1, 2013) 
(failing to distinguish between marijuana possession arrests for medicinal and recreational use).  
 36. See generally SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH 
& HUMAN SERVS., supra note 22, at 1 (noting that marijuana was considered an illicit drug for the 
purposes of the survey without distinguishing the purpose of its use); LLOYD D. JOHNSTON ET AL., U.S. 
DEP‘T OF HEALTH & HUMAN SERVS., NATIONAL SURVEY RESULTS ON DRUG USE FROM THE 
MONITORING THE FUTURE STUDY, 1975–1997 6 (1998) (noting that marijuana use increased among 
secondary school students without specifying the purpose of that use). 
 37. See generally Paul Armentano, Behind the Lack of Medical Marijuana Research: Feds 
Disallowing Initiatives, HUFFPOST POLITICS: THE BLOG (Jan. 28, 2010, 2:21 PM), 
http://www.huffingtonpost.com/paul-armentano/behind-the-lack-of-medica_b_439415.html (explaining 
that the federal government must approve all clinical and preclinical research of marijuana, but thus far, 
only funds research on the negative impacts of marijuana use). 
  
64 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 16:59 
C.  No research exists on the reaction of state medical boards to decriminalization 
statutes 
To date, no research has been conducted that examines the actions of state 
medical boards in jurisdictions that have decriminalized medical marijuana.38 This 
lack of knowledge regarding medical board practices, guidelines, policies, and 
standards of care relating to physicians who recommend medical marijuana creates 
a vacuum in understanding the role that medical boards can, and possibly should, 
play in ensuring that physicians recommend medical marijuana appropriately. In 
their role as the entities that license and discipline physicians within a state, state 
medical boards influence physician behavior by selecting which cases to 
investigate and prosecute.39 Medical boards also have the authority to issue 
guidance or recommendations to update physicians about state law, assist 
physicians in their practice, or warn against certain practices.40 Without such 
research, however, it is difficult to know what effect MML actually has on doctors‘ 
prescription habits and practices. 
D.  The significance of differing laws relating to marijuana dispensaries is 
unknown 
Some MML authorizes the creation of a system of licensed dispensaries to 
distribute marijuana.41 Dispensaries are not licensed pharmacies that operate under 
the control of state boards of pharmacy, although apparently in California the state 
board of pharmacy has been given the responsibility of inspecting dispensaries.42 A 
licensed pharmacy would need a DEA permit to dispense controlled substances and 
DEA would not issue a permit to a pharmacy to distribute medical marijuana.43 
Dispensaries are a relatively novel concept and not comparable to other health care 
delivery centers.44 There are few guidelines regarding how best to run a dispensary, 
 
 38. See ANDERSON & REES, supra note 20, at 19 (commenting on the lack of research on the impact 
of state MML). 
 39. See, e.g., CAL. BUS. & PROF. CODE § 2220 (2013) (authorizing the California medical board to 
enforce the provisions within the chapter against physicians and surgeons); Medical Marijuana, THE 
MED. BD. CAL., http://www.mbc.ca.gov/medical_marijuana.html (last visited Apr. 1, 2013) (providing 
the California Medical Board‘s recommendations on points for physicians to consider before 
recommending medical marijuana in order to avoid disciplinary action). 
 40. See generally Drew Carlson & James N. Thompson, The Role of State Medical Boards, 7 
VIRTUAL ETHICS 1 (2005), http://virtualmentor.ama-assn.org/2005/04/pdf/pfor1-0504.pdf (discussing 
the role of state medical boards and how they are responsible for establishing standards and guidelines 
for physicians). 
 41. See Hoffmann & Weber, supra note 12, at 1456 tbl.2 (listing states that have enacted MML that 
allow for establishment of dispensaries in various forms). 
 42. CAL. BD. OF PHARMACY, 2013 LAWBOOK FOR PHARMACY 14 (2009). 
 43. 21 U.S.C. § 822 (1999). 
 44. See generally LEIYU SHI & DOUGLAS A. SINGH, ESSENTIALS OF THE U.S. HEALTH CARE 
SYSTEM 24 (2d ed. 2010) (describing the various subsystems that provide the framework for health care 
delivery in the United States). 
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although private citizens and organizations have promulgated some best practice 
guidelines.45 To date, no research has compared or contrasted the practices and 
characteristics of dispensaries in different states, although there is one study of 
dispensary policies within California.46  
While a handful of studies compare and contrast different MML,47 no attempt 
has been made to analyze the components of the different legal frameworks in 
order to place them on a continuum so that the impact of different legal structures 
can be compared against specific outcome measures.48 In Part III, potential models 
for gathering information on differing policies and outcomes are proposed.  
III.  POTENTIAL MODELS: DISPENSARIES, REMS, AND  
PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPS) 
While each state‘s MML is designed to meet similar goals, the laws vary in 
many important ways, including limits on the quantity of marijuana that may be 
possessed or cultivated,49 authorization to sell marijuana through dispensaries,50 
regulation of dispensaries,51 approved conditions of use,52 regulation of use,53 
 
 45. See, e.g., Eric Markowitz, How to Open a Medical Marijuana Dispensary, INC. (May 27, 
2011), http://www.inc.com/guides/201105/how-to-open-a-medical-marijuana-dispensary.html (offering 
insight on expected costs and revenues to opening a medical marijuana dispensary).  
 46. NANCY J. WILLIAMS, ET AL., CAL. CTR. FOR POPULATION RESEARCH, EVALUATING MEDICAL 
MARIJUANA DISPENSARY POLICIES: SPATIAL METHODS FOR THE STUDY OF ENVIRONMENTALLY-BASED 
INTERVENTIONS (2011). 
 47. See Robert MacCoun & Peter Reuter, Keynote Address at the Michigan State University 
Journal of Medicine & Law Symposium: Exploring Drug Depenalization: The Next Step After Proposal 
1 (Apr. 10, 2009) (distinguishing Michigan‘s medical marijuana law from California‘s law); Hoffmann 
& Weber, supra note 12, at 1453–56 (discussing variations in state medical marijuana laws, including 
differences in covered medical conditions and allowable quantities). 
 48. See infra Part III (discussing potential models to accomplish this goal). 
 49. See 18 Legal Medical Marijuana States and DC: Laws, Fees, and Possession Limits, PROCON, 
http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881 (last updated Feb. 22, 2013, 
5:21 PM) (comparing medical marijuana state laws in terms of the year passed, fee, and possession 
limit); Hoffmann & Weber, supra note 12, at 1454, 1456 tbl.2 (reporting that most states regulate the 
amount of marijuana that patients or caretakers may possess and giving examples of variations in state 
amount requirements).  
 50. See Hoffmann & Weber, supra note 12, at 1456 tbl.2 (demonstrating that while California, 
Maine, Rhode Island, and New Jersey allow marijuana dispensaries, other states including Alaska, 
Oregon, and Washington do not). 
 51. See id. at 1454 (reporting that most state laws do not have specific provisions regulating 
dispensaries, whereas California allows dispensing of medical marijuana through cooperatives or 
collectives).  
 52. See id. at 1454, 1455 tbl.1 (reporting that different states allow use of medical marijuana for 
different diseases and conditions; for instance, Michigan and Rhode Island allow marijuana use for 
Hepatitis C while California and New Jersey do not allow such use).  
 53. Compare CAL. HEALTH & SAFETY CODE § 11362.79 (West 2007 & Supp. 2013) (providing that 
California prohibits a qualified patient from smoking medical marijuana in certain places including 
where smoking is illegal, in or within 1,000 feet of school, or on a school bus), with ALASKA STAT. § 
17.37.040 (2012) (noting that in Alaska, medical use of marijuana is prohibited in any place of 
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including location of use, responsibilities of physicians (e.g., whether alternative 
treatment was attempted),54 regulation of caregivers,55 ability of local governments 
to set additional controls on cultivation and distribution,56 establishment of 
registries,57 and whether qualified users are protected from arrest and/or 
prosecution.58 In broader terms, MML creates legal frameworks that vary in the 
balance each jurisdiction creates between access and restrictiveness. 
A.  The Role of Dispensaries: A New Kind of Pharmacy? 
Marijuana, including medical marijuana, is a Schedule I controlled 
dangerous substance.59 As such, its possession and/or use in the United States is 
illegal.60 As far as the federal government, through the Drug Enforcement 
Administration (DEA) is concerned, it has no acceptable medical use, thus 
maintaining marijuana‘s Schedule I status.61 Residents in states with medical 
marijuana decriminalization statutes cannot use the U.S. Constitution, 
principally the Commerce Clause, as a shield.62 In 2009, the Department of 
Justice issued a memorandum to U.S. Attorneys that federal resources should 
not be used to prosecute people whose actions are in compliance with state laws 
 
employment, in any medical facility monitored by the department or the Department of Administration, 
on or within 500 feet of school grounds, or on a school bus).  
 54. See MARIJUANA POLICY PROJECT, STATE-BY-STATE MEDICAL MARIJUANA LAWS: HOW TO 
REMOVE THE TREAT OF ARREST app. H (2011), available at 
http://www.mpp.org/assets/pdfs/library/State-by-State-Laws-Report-2011.pdf (noting that when 
physicians issue a recommendation or certification to patients authorizing use of medical marijuana, 
some states require that physicians discuss the risks and benefits of medical marijuana use and to include 
in the certification that the patient has an approved condition).  
 55. Compare CAL. HEALTH & SAFETY CODE § 11362.7(e) (West 2007 & Supp. 2013) (requiring a 
primary caregiver to be at least 18 years old in California), with ALASKA STAT. § 17.37.010(d) (2012) 
(requiring a primary caregiver in Alaska to be at least 21 years old).  
 56. Compare CAL. HEALTH & SAFETY CODE § 11362.83 (West 2007 & Supp. 2013) (allowing 
cities or local counties in California to enact other laws consistent with the state medical marijuana law), 
with ALASKA STAT. §§ 17.37.010–080 (2012) (providing no provisions giving local governments 
authority to enact additional controls). 
 57. See Hoffmann & Weber, supra note 12, at 1454, 1456 tbl.2. 
 58. See id.  
 59. Controlled Substances, U.S. Dep‘t of Justice, 3 (Sept. 6, 2012), 
http://www.deadiversion.usdoj.gov/schedules/orangebook/e_cs_sched.pdf. 
 60. See id. See also Marsha N. Cohen, Breaking the Federal/State Impasse Over Medical 
Marijuana: A Proposal, 11 Hastings Women‘s L.J. 59, 60–61 (2000) (discussing the prohibition of use 
and possession of Schedule I controlled substances). 
 61. See OFFICE OF DIVERSION CONTROL, Controlled Substance Schedules, U.S. DEP‘T OF JUSTICE, 
http://www.deadiversion.usdoj.gov/schedules/ (last visited Apr. 1, 2013) (noting that marijuana, as a 
Schedule I Controlled Substance, has no accepted medical use and a high likelihood for abuse). 
 62. See Gonzales v. Raich, 545 U.S. 1, 22 (2005) (holding that application of the Controlled 
Substance Act to intrastate growers and users of medical marijuana was within Congress‘s Commerce 
Clause powers, meaning it cannot be used as a shield to prevent criminal liability for marijuana 
manufacturing). 
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providing for use of medical marijuana.63 It is important to note that this 
memorandum did not change the law, was not binding on the U.S. Attorneys, 
and that the Administration could easily reverse its position.64 
In fact, despite the policy stated above, there appears to be a lessening of the 
federal tolerance for medical marijuana at least as it relates to dispensaries. A 
number of states allow these dispensaries, California having the largest number, but 
dispensaries were not necessarily included in the federal government‘s tolerance of 
state medical marijuana decriminalization laws.65 In October 2011, California‘s 
four U.S. Attorneys, including Sacramento‘s U.S. Attorney, held a press conference 
to announce the federal government‘s intention to crack down on medical 
marijuana dispensaries.66 The federal government sent out letters to dispensaries 
and their landlords in San Francisco, San Diego, and Marin County that 
dispensaries were in violation of federal law.67 The letters instructed the landlords 
to evict their dispensary tenants.68 They also directed the dispensaries to close up 
shop within forty-five days; otherwise, both the dispensary owners and the 
landlords would be arrested and prosecuted.69 The government noted that it was 
focusing only on those dispensaries that were ―clearly profiteering‖ from the 
medical marijuana industry.70 However, by December 2011, in Sacramento, 
California, ninety-one dispensaries were shut down, leaving only eight.71 In 
Montana, in March 2011, federal agents raided medical marijuana dispensaries 
around the state.72 More recently, in July 2012, the Department of Justice served 
Harborside Health Center‘s property owners with commercial property forfeiture 
 
 63. Memorandum from James M. Cole, Deputy Att‘y Gen., to U.S. Att‘ys (June 29, 2011), 
available at http://www.justice.gov/oip/docs/dag-guidance-2011-for-medical-marijuana-use.pdf. 
 64. See id. (emphasizing that enforcement of the Controlled Substances Act ―remains a core 
priority‖ and that the Ogden Memo is only meant to guide U.S. Attorneys in exercising their ―broad 
discretion‖ in prosecuting federal criminal matters). 
 65. See id. (noting that state-authorized dispensaries are not shielded from federal prosecution or 
enforcement actions).  
 66. See Peter Hecht, U.S. Attorneys: Marijuana Dispensaries in California Aren’t Legal, 
SACRAMENTO BEE, Oct. 7, 2011, http://blogs.sacbee.com/crime/archives/2011/10/us-attorneys-
marijuana-dispensaries-in-california-arent-legal.html (reporting that federal prosecutors would be 
bringing criminal complaints and forfeiture actions against numerous California medical marijuana 
dispensaries).  
 67. See Alexander Leach, The Federal Government is Cracking Down on Medical Marijuana, 
EXAMINER, Oct. 8, 2011, http://www.examiner.com/liberal-in-sacramento/the-federal-government-is-
cracking-down-on-medical-marijuana. 
 68. See id. 
 69. See id.  
 70. See id.  
 71. See Alexander Leach, Medical Marijuana Dispensaries are Closing Up Shop, EXAMINER, Dec. 
5, 2011, http://www.examiner.com/article/medical-marijuana-dispensaries-are-closing-up-shop.  
 72. See Gwen Florio, Feds Raid Medical Marijuana Operations in Missoula, Statewide, 
MISSOULIAN, Mar. 14, 2011, http://missoulian.com/news/local/feds-raid-medical-marijuana-operations-
in-missoula-statewide/article_eae07e58-4e7d-11e0-aa23-001cc4c03286.html. 
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proceedings because it violates federal law.73 Harborside Health Center serves over 
100,000 cannabis patients in two northern California cities.74 
B.  FDA Approval and Risk Evaluation and Mitigation Strategies (REMS) 
The use of marijuana for medical purposes is prohibited at the federal level 
because of the status of marijuana as a Schedule I drug under the Controlled 
Substances Act.75 Thus, unlike other drugs in the United States, medical marijuana 
has not undergone approval as a new drug by the Food and Drug Administration 
(FDA) and has not been subject to the same level of rigorous clinical trials that is 
true for approved drugs.76 Nor has marijuana been subject to the establishment of 
safety standards that FDA may establish for drugs with a profile of side effects or 
potentially harmful public health effects.77  
The FDA, for example, has developed Risk Evaluation and Mitigation 
Strategies (REMS) for prescription opioid analgesics due to growing concerns 
about their abuse and diversion. Over the past decade, the medical use of opioid 
analgesics (OAs) have markedly increased, with OA prescriptions rising at twice 
the rate of non-OA prescriptions.78 Parallel increases in OA abuse and diversion 
have accompanied the rise in medical OA use.79 In 2010, 12.2 million United States 
citizens aged twelve and older reported past-year non-medical use of prescription 
OAs, a ten percent increase from 2002, making OAs the most abused drugs after 
marijuana.80 Consequences of OA abuse include death from poisoning and 
 
 73. See Malia Wollan, Oakland Files Suit Against U.S. to Prevent Closing of Marijuana 
Dispensary, N.Y. TIMES, Oct. 12, 2012, at A18 (reporting that U.S. Attorney Melinda Haag issued a 
forfeiture notice on two of Harborside‘s properties). 
 74. See Carly Schwartz, Harborside Health Center Community Suffers Under Federal Cannabis 
Crackdown, HUFFINGTON POST (Sept. 4, 2012, 4:02 PM), http://www.huffingtonpost.com/2012/09/04/ 
harborside-health-center-_n_1853344.html.  
 75. See supra notes 59–61 and accompanying text. 
 76. See JOY ET AL., supra note 1, at 196 fig.5.1, 202 (displaying the various stages of testing that 
drugs must undergo before receiving approval for marketing in the United States).  
 77. See 21 C.F.R. § 201.57(c)(6) (2012) (authorizing FDA to revise a drug‘s labeling when there is 
―reasonable evidence of a causal association‖ between the drug and a potentially harmful health effect).  
 78. See Bridget M. Kuehn, Opioid Prescriptions Soar: Increase in Legitimate Use as Well as 
Abuse, 297 JAMA 249, 249 (2007) (noting that opioid analgesics are now ―among the most prescribed 
drugs‖ in the United States and providing evidence of the rise of OA prescriptions).  
 79. See id. at 249–50 (noting a simultaneous rise in legitimate medical OA use and illicit OA 
abuse); see also SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH & 
HUMAN SERVS., RESULTS FROM THE 2007 NATIONAL SURVEY ON DRUG USE AND HEALTH 250 tbl.G.1 
(2008).(illustrating the rise in illicit use of prescription pain relievers from 2002 to 2007).  
 80. Compare SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. DEP‘T OF HEALTH & 
HUMAN SERVS., RESULTS FROM THE 2002 NATIONAL SURVEY ON DRUG USE AND HEALTH: DETAILED 
TABLES tbl.1.1A (2005) (finding that 10,992,000 persons aged twelve or older reported past-year non-
medical use pain relievers in 2002), with SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., U.S. 
DEP‘T OF HEALTH & HUMAN SERVS., RESULTS FROM THE 2010 NATIONAL SURVEY ON DRUG USE AND 
HEALTH: DETAILED TABLES tbl.1.54A (2012) (finding that 12,213,000 persons aged twelve or older 
reported past-year non-medical use pain relievers in 2010). 
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overdose,81 increases in an already overburdened treatment system, with non-heroin 
OA abuse treatment admissions increasing from 22,600 admissions in 1999 to over 
142,000 in 2009.82 The economic burden of OA abuse and dependence remains 
substantial, with total societal costs estimated at $55 billion.83 It would be difficult 
if not impossible to develop REMS for medical marijuana due in part to the 
inability to clearly identify the plant a particular individual might be using.84 There 
is obviously no standardization since it is not even acknowledged by the federal 
government as having an accepted medical use.85 That is not to say that a medical 
body might be able to develop some guidelines for its safe use and publish those in 
some standard form. 
Although FDA-approved products that contain cannabis (e.g., Marinol®) 
exist, there has been a sustained push for states to decriminalize medical 
marijuana.86 FDA approval of medical marijuana as it currently exists, even if 
allowed under the federal Food Drug and Cosmetic Act, is impractical—marijuana 
used for medical purposes is not a single plant variety or strain.87 Indeed, it is the 
variability in plant differences in potency and effects, as well as the flexibility in 
dosage and administration, that lead many patients to prefer plant-sourced cannabis 
 
 81. See Leonard Paulozzi et al., CDC Grand Rounds: Prescription Drug Overdoses – a U.S. 
Epidemic, 61 Morbidity & Mortality Wkly. Rep. (Ctrs. for Disease Control & Prevention, Atlanta, Ga.), 
Jan. 13, 2012, at 10, 10 (commenting that OAs are responsible for an increasing number of unintentional 
overdose deaths); Margaret Warner et al., Increase in Fatal Poisonings Involving Opioid Analgesics in 
the United States, 1999–2006, 22 NCHS DATA BRIEF (Nat‘l Ctr. for Health Statistics, Hyattsville, Md.), 
Sept. 2009, at 1, 1 (finding OA-related deaths are responsible for an increasing percentage of drug 
poisoning deaths); Leonard Paulozzi et al., Increasing Deaths from Opioid Analgesics in the United 
States, 15 Pharmacoepidemiology & Drug Safety 618, 621–22 (2006) (noting that OA poisoning is the 
most rapidly increasing category of poisoning death of any major drug). 
 82. Compare CTR. FOR BEHAVIORAL HEALTH STATISTICS & QUALITY, SUBSTANCE ABUSE & 
MENTAL HEALTH SERVS. ADMIN, 1999 Substance Abuse Treatment Admissions by Primary Substance 
of Abuse According to Sex, Age Group, Race, and Ethnicity, TREATMENT EPISODE DATA SET, 
http://wwwdasis.samhsa.gov/webt/quicklink/US99.htm (last visited Mar. 30, 2013) (citing 22,637 non-
heroin OA abuse treatment admissions in 1999), with CTR. FOR BEHAVIORAL HEALTH STATISTICS & 
QUALITY, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., 2009 Substance Abuse Treatment 
Admissions by Primary Substance of Abuse According to Sex, Age Group, Race, and Ethnicity, 
TREATMENT EPISODE DATA SET, http://wwwdasis.samhsa.gov/webt/quicklink/US09.htm (last visited 
Apr. 1, 2013) (citing 143,564 non-heroin OA abuse treatment admissions in 2009). 
 83. Howard Birnbaum et al., Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse 
in the United States, 12 Pain Med. 657, 661 (2011) (estimating the total societal costs of OA abuse to be 
55.7 billion dollars in 2007 and providing a breakdown of those costs).  
 84. See Shannon L. Datwyler & George D. Weiblen, Genetic Variation in Hemp and Marijuana 
(Cannabis sativa L.) According to Amplified Fragment Length Polymorphisms, 51 J. FORENSIC SCI. 371, 
371 (2006) (noting the substantial variation in drug content among cannabis plants).  
 85. See supra notes 59–61 and accompanying text. 
 86. See PROCON, supra note 3. 
 87. See JOY ET AL., supra note 1, at 215–16 (outlining the regulatory hurdles medical marijuana 
cultivators would face in seeking FDA approval even if it were allowed under the Food Drug and 
Cosmetic Act, such as difficulties meeting the safety and efficacy standards as both a botanical product 
and as a drug delivered through smoke inhalation). 
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over Marinol® and other synthetic prescription products.88 Cannabis plants have 
psychoactive properties, produced from the over eighty phenols and flavonoids in 
the plants; many of these compounds are thought to have medicinal properties.89 In 
particular, cannabis plants produce a unique family of terpenophenolic compounds 
called cannabinoids.90 Two cannabinoids of particular medical utility include Delta-
9-tetrahydroccannabinol (THC), which has psychoactive properties, and 
Cannabidiol (CBD), which does not.91 Marinol® only includes THC, and does not 
include cannabidiol or other phenolic or flavonoid compounds.92  
Medical marijuana would be a prime candidate for a REM if approved by 
FDA as a new drug because there would likely be an authorized source such as the 
University of Mississippi where the plant variety/species would be standardized 
and appropriate information about its use and potential risks could be developed 
with some level of confidence.93 Even without FDA-approval, however, states 
could adapt REMS-like requirements as part of their MML.94 To date, no state has 
implemented such safeguards.95 
C. Prescription Drug Monitoring Programs 
In response to the growing epidemic of prescription drug abuse, states have 
implemented prescription drug monitoring programs (PDMPs), state-level 
registries that monitor the prescribing, dispensing, and purchase of prescribed 
 
 88. See generally Ernest Small & H.D. Beckstead, Common Cannabinoid Phenotypes in 350 Stocks 
of Cannabis, 36 Lloydia 144 (1973) (analyzing variances in content among 350 unique strains of 
cannabis); Cohen, supra note 60, at 71–72 (noting that Marinol® fails to satisfy patient due to its 
inflexible dosage and administration, adverse side-effects, and high cost). 
 89. Geraint B. Osborne & Curtis Fogel, Understanding the Motivations for Recreational Marijuana 
Use Among Adult Canadians, 43 SUBSTANCE USE & MISUSE 539, 551 (2008). 
 90. Id.  
 91. See Teresa Iuvone et al., Neuroprotective Effect of Cannabidiol, a Non-psychoactive 
Component from Cannabis sativa, on ß-amyloid-induced Toxicity in PC12 cells, 89 J. NEUROCHEMISTRY 
134, 135 (2004). 
 92. PAUL ARMENTANO, NORML, MARINOL VERSUS NATURAL CANNABIS: PROS, CONS AND 
OPTIONS FOR PATIENTS 5 (2005), available at 
http://norml.org/pdf_files/NORML_Marinol_vs_Natural_Cannabis.pdf. 
 93. See FDA Partnership, U. MISS. SCH. PHARMACY, NAT‘L CENTER FOR NAT. PRODUCTS RES., 
http://www.pharmacy.olemiss.edu/ncnpr/fdapartnership.html (last visited Apr. 1, 2013) (stating that 
FDA and the University of Mississippi School of Pharmacy have partnered to develop a research 
program to specifically study botanical supplements). 
 94. See FOOD & DRUG ADMIN., DRAFT GUIDANCE: FORMAT AND CONTENT OF PROPOSED RISK 
EVALUATION AND MITIGATION STRATEGIES (REMS), REMS ASSESSMENTS, AND PROPOSED REMS 
MODIFICATIONS 2 (2009), available at http://www.fda.gov/downloads/Drugs/Guidances/ 
UCM184128.pdf (stating that FDA only requires a REMS when it needs to ensure the benefits of a 
drug outweigh its risks). 
 95. See AM. SOC‘Y OF ADDICTION MED., PUBLIC POLICY STATEMENT ON MEDICAL MARIJUANA 
(2010), available at http://www.asam.org/docs/publicy-policy-statements/1medical-marijuana-4-
10.pdf?sfvrsn=0 (explaining that even in states that have legalized marijuana, the marijuana is not 
standardized or subject it to quality controls). 
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medications categorized as controlled substances.96 A PDMP is defined as a 
―statewide electronic database which collects designated data on substances 
dispensed in the state.‖97 This implementation process took many years, as most 
states have been historically resistant to passing laws where the state itself would 
have access to a patient‘s medical record.98 Indeed, this issue of privacy has been a 
strong objection on the part of those who oppose state laws.99 
As of 2012, forty-eight states had enacted or authorized a PDMP;100 and of 
these, at the time of publication, forty-three are operational.101 Despite widespread 
adoption, few studies have evaluated PDMP effectiveness in reducing prescription 
abuse or assessed their impact on patient care and outcomes.102 State variability in 
PDMP design, scope, operationalization, and rigor imposes unique challenges in 
assessing PDMP effectiveness.103 Although all PDMPs use electronic technology to 
collect, transmit, and organize prescription data,104 three states (New York, 
California, and Texas) supplement their electronic system with ‗hard copy‘ 
serialized and/or tamper-proof paper forms, a deterrent to prescription alterations 
and forgeries.105 Critics of PDMPs contend these forms reduce patient access to 
 
 96. See OFFICE OF DIVERSION CONTROL, State Prescription Drug Monitoring Programs, U.S. 
DEP‘T OF JUSTICE, http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm (last updated Oct. 2011). 
 97. Id. 
 98. See KAREN BLUMENSCHEIN ET AL., UNIV. OF KY., REVIEW OF PRESCRIPTION DRUG 
MONITORING PROGRAMS IN THE UNITED STATES 3–4 (2010) (recommending that PDMP programs not 
allow data to be open to the public or subject to open record laws amidst privacy concerns). 
 99. See, e.g., California Medical Privacy Fact Sheet C4: Your Prescriptions and Your Privacy, 
PRIVACY RIGHTS CLEARINGHOUSE (July 2012), https://www.privacyrights.org/fs/fsC4/CA-medical-
prescription-privacy#prescription-drug-monitoring-program (stating that PDMPs create privacy 
concerns by putting users‘ information into a database accessible to other people and governmental 
entities). 
 100. See Status of State Prescription Drug Monitoring Programs, NAT‘L ALLIANCE FOR MODEL ST. 
DRUG LAWS, 2 (July 2, 2012), http://www.namsdl.org/documents/PMPProgramStatus07022012.pdf. 
 101. Id. 
 102. See Jeanmarie Perrone & Lewis S. Nelson, Medication Reconciliation for Controlled 
Substances–An ―Ideal‖ Prescription-Drug Monitoring Program, 366 NEW ENG. J. MED. 2341, 2341 
(2012) (noting the limited amount of research on PDMP effectiveness is a result of differing PDMP 
designs across states). 
 103. Id. 
 104. See id. (discussing how PDMPs have benefited from technological advancements). 
 105. See N.Y. STATE DEP‘T OF HEALTH, WHAT EVERY PRACTITIONER NEEDS TO KNOW ABOUT 
CONTROLLED SUBSTANCE PRESCRIBING 2 (2009), available at http://www.health.ny.gov/ 
publications/1477.pdf (describing the requirement of New York practitioners to keep written records of 
all prescribed controlled substances); Scott M. Fishman, Repeal of Triplicate Prescribing and the New 
Security Paper Prescription Requirement in California, CSA BULLETIN (Cal. Soc‘y of 
Anesthesiologists, San Mateo, Cal.), Jan.–Mar., 2004, at 2 (stating that California requires the use of 
tamper-resistant security paper for all controlled drugs prescribed); Texas Prescription Program, TEX. 
DEP‘T PUB. SAFETY, http://www.txdps.state.tx.us/RegulatoryServices/prescription_program/ 
prescriptionforms.htm (last visited Apr. 1, 2013) (stating that Texas practitioners use single or multiple 
copy forms issued by the state to write prescriptions for certain controlled substances). 
  
72 JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 16:59 
necessary medications due to the ―chilling effect‖ on prescribers who fear scrutiny 
of their practices.106  
Since the most comprehensive empiric work evaluating PDMPs was 
conducted a decade ago on the New York paper-based benzodiazepine PDMP 
program,107 only a few single-state108 and multiple-state109 analyses have been 
conducted. This research finds PDMPs are associated with reductions in 
prescribing of targeted medications. Although one study found PDMP states 
experienced both lower OA supply and treatment admissions than non-PDMP 
states,110 another study found PDMPs that communicated with prescribers and 
pharmacists achieved a ten percent reduction in the use and abuse of monitored 
prescription drugs.111 To date, only one has documented opioid analgesic 
 
 106. See, e.g., Jing Wang & Paul J. Christo, The Influence of Prescription Monitoring Programs on 
Chronic Pain Management, 12 PAIN PHYSICIAN 507, 510 (2009) (noting that physicians may under-treat 
pain in order to avoid investigations by regulatory agencies). 
 107. In 1989, New York State implemented regulations requiring all benzodiazepines prescriptions 
to be written on special triplicate prescription forms, a measure that had significant effects on 
benzodiazepine use. See, e.g., Benzodiazepines: Additional Effects of The Triplicate Program, 90 N.Y. 
ST. J. MED. 273, 273 (1990); Benzodiazepines: Prescribing Declines Under Triplicate Program, 90 
N.Y. ST. J. MED. 218, 218 (1990); Michael Weintraub et al., Consequences of The 1989 New York State 
Triplicate Benzodiazepine Prescription Regulations, 266 JAMA 2392, 2392 (1991); Sallie-Anne 
Pearson et al., Racial Disparities In Access Following Regulatory Surveillance of Benzodiazepines, 166 
ARCHIVES INTERNAL MED. 572, 575 (2006); Anita K.Wagner et al., Effects of State Surveillance on New 
Post-Hospitalization Benzodiazepine Use, 15 INT‘L J. QUALITY HEALTH CARE 423, 426 fig.1, 427 
(2003). 
 108. See, e.g., Aaron M. Gilson et al., Time Series Analysis of California’s Prescription Monitoring 
Program: Impact On Prescribing And Multiple Provider Episodes, 13 J. PAIN 103, 104 (2012) 
(analyzing California‘s use of tamper-resistant prescription forms to determine whether forms affected 
doctors‘ prescribing practices for Schedule II opioids); Katherine A. Sigler et al., Effects of Triplicate 
Prescription Law On Prescribing of Schedule II Drugs, 41 AM. J. HOSP. PHARMACY 108, 108 (1984) 
(studying Texas‘ triplicate prescription program‘s prescribing patterns for Schedule II substances); 
Nathaniel Katz et al., Usefulness of Prescription Monitoring Programs For Surveillance — Analysis of 
Schedule II Opioid Prescription Data In Massachusetts, 1996–2006, 19 PHARMACOEPIDEMIOLOGY & 
DRUG SAFETY 115, 116 (2010) (analyzing Massachusetts‘ prescription monitoring program and opioid 
prescribing and usage trends). 
 109. See e.g., Leonard J. Paulozzi et al., Prescription Drug Monitoring Programs And Death Rates 
From Drug Overdose, 12 PAIN MED. 747, 749 (2011) (comparing drug overdose mortality rates in states 
with PDMPS with states without PDMPs); U.S. GEN. ACCOUNTING OFFICE, GAO-02-634, 
PRESCRIPTION DRUGS: STATE MONITORING PROGRAMS PROVIDE USEFUL TOOL TO REDUCE DIVERSION 
15 (2002) (reporting the success of PDMP programs in certain states, including Kentucky, Nevada, and 
Utah); Richard M. Reisman et al., Prescription Opioid Usage And Abuse Relationships: An Evaluation 
of State Prescription Drug Monitoring Program Efficacy, 3 SUBSTANCE ABUSE: RES. & TREATMENT 41, 
43 (2009) (studying PDMP programs in several states between 1997 and 2003); Ronald Simeone & 
Lynn Holland, An Evaluation of Prescription Drug Monitoring Programs, SIMEONE ASSOCIATES, INC. 2 
(Sept. 1, 2006), http://www.simeoneassociates.com/simeone3.pdf (studying the impact of PDMPs in 
curbing drug supply and abuse in the United States between 1997 and 2003). 
 110. Reisman et al., supra note 109, at 46–47. 
 111. Simeone & Holland, supra note 109, at 40.  
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prescribing changes associated with electronic-only PDMPs,112 although another 
study found changing from a ―triplicate‖ paper-based program to one requiring an 
electronic security form resulted in statistically significant increases in Schedule II 
opioid analgesics, especially short-acting oxycodone and hydrocodone.113 Other 
research has documented that PDMPs with paper prescription overlays experienced 
both lower prescription OA use and overdose mortality rates than electronic-only 
PDMPs.114 Compared to non-PDMP states, those with prescription monitoring 
programs utilized greater amounts of Schedule III hydrocodone and non-
significantly lower amounts of Schedule II opioid analgesics.115 It is important to 
note that reductions in use of prescription medications targeted by PDMPs does not 
translate into a corresponding reduction in their abuse or diversion.116 To date, no 
research on PDMPs has adequately differentiated the effectiveness of PDMPs in 
reducing abuse and diversion versus reducing medical access to controlled 
prescription medications.117 
As noted previously, the widespread acceptance of PDMPs has not resulted in 
a widespread understanding of their intended and unintended impacts. PDMPs 
remain contentious, with their supporters118 and detractors.119 The specter of a 
chilling effect on prescribing (and dispensing) for those patients in genuine medical 
need has been a prime motivator for objections.120 Despite these concerns, the DEA 
 
 112. Linda Simoni-Wastila & Jingjing Qian, Influence of Prescription Monitoring Programs On 
Analgesic Utilization By An Insured Retiree Population, 21 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 
1261, 1262 (2012). 
 113. Gilson et al., supra note 108, at 106. 
 114. Simoni-Wastila & Qian, supra note 112, at 1262 (finding that paper and/or form-based 
monitoring systems produced a reduction in the use of opioid analgesics); Paulozzi et al., supra note 
109, at 752 (noting that PDMPs resulted in lower opioid overdose mortality rates in California, New 
York and Texas). 
 115. Paulozzi et al., supra note 109, at 751.  
 116. See id. at 750–51.  
 117. See Wang & Christo, supra note 106, at 510 (discussing conflicting results regarding the effects 
of PDMPs on doctors‘ prescribing behaviors and opioid drug abuse rates). 
 118. See Amy Pavuk, States Could Makes Better Use of Prescription Data To Fight Drug Abuse, 
Study Finds, ORLANDO SENTINEL Sept. 20, 2012, http://articles.orlandosentinel.com/2012-09-
20/news/os-pdmp-study-florida-20120920_1_prescription-drug-prescriptions-from-multiple-doctors-
florida-s-pdmp (discussing how supporters of Florida‘s PDMP believe it contributes to reduced drug 
abuse rates). 
 119. See THOMAS CLARK ET AL., BRANDEIS UNIV., PRESCRIPTION DRUG MONITORING PROGRAMS: 
AN ASSESSMENT OF THE EVIDENCE FOR BEST PRACTICES 4 (2012), 
http://www.pewhealth.org/uploadedFiles/PHG/Content_Level_Pages/Reports/PDMP%20Update%201-
31-2013.pdf (noting public and private supporters, including the Drug Enforcement Agency, Department 
of Justice, and Purdue Pharma, the manufacturer of OxyContin); Felisa Cardone, Lawmakers May 
Cancel State Database Used To Fight Prescription-Drug Abuse, DENVER POST, Mar. 7, 2011, 
http://www.denverpost.com/news/ci_17553082 (discussing Colorado lawmakers‘ distrust of the state 
PDMP amidst privacy concerns and a lack of information to the public). 
 120. See KRISTIN M. FINKLEA ET AL., CONG. RESEARCH SERV., R42593, PRESCRIPTION DRUG 
MONITORING PROGRAMS 20 (2012) (discussing various organizations‘ concerns that PDMPs may limit 
doctors‘ ability to adequately treat patient pain). 
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and other advocates for PDMPs have been successful in convincing states to adopt 
PDMPs.121 Probably the most significant tool in the DEA‘s recruiting repertoire is 
the grant money from the federal government to states for program implementation 
once PDMP legislation is passed.122 
PDMPs are not without their benefits. They may be used to authenticate 
prescribers, pharmacies, and patients.123 They may be helpful in emergency 
departments and other urgent care settings to assist in the treatment of patients who 
present without known medical history.124 The success of PDMPs may depend, in 
part, on which area of the state is responsible for tracking prescriptions.125 Is it law 
enforcement, such as the Attorney General‘s office, or is it a health care entity, 
such as the state public health department? Similarities abound with medical 
marijuana. For instance, the Vermont Medical Marijuana Registry is housed in the 
state‘s criminal information center.126 Thus, as with the problem of prescription 
opioid analgesics, such decisions are important for determining the effectiveness of 
medical marijuana laws in providing access when needed, and preventing diversion 
as possible.127  
  
 
 121. See U.S. GEN. ACCOUNTING OFFICE, supra note 109, at 20 (noting how the DEA has been 
supportive of states that start PDMP programs). 
 122. Id. See, e.g., BUREAU OF JUSTICE ASSISTANCE, U.S. DEP‘T OF JUSTICE, OMB NO. 1121-0329, 
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM FY 2012 COMPETITIVE GRANT 
ANNOUNCEMENT 3–4 (2012), available at https://www.bja.gov/Funding/12PDMPsol.pdf (describing a 
federal grant to assist states in starting PDMPs). 
 123. See IJIS INST., PMP COMMITTEE PHASE II PMIX PILOT PROJECT SURVEY OF STATE 
PRESCRIPTION MONITORING PROGRAMS 19–20 (2007), available at 
http://www.nascsa.org/News/IIJISpmixPMPSurveyResults1.07.pdf.  
 124. See David F. Baehren et al., A Statewide Prescription Monitoring Program Affects Emergency 
Department Prescribing Behaviors, 56 ANNALS EMERGENCY MED., 19, 22 (2010) (reporting that 
PDMPs are helpful in measuring patients‘ patterns of seeking out opiate medications). 
 125. See generally State/Territory/District Contacts, ALLIANCE STS. WITH PRESCRIPTION 
MONITORING PROGRAMS, http://www.pmpalliance.org/content/stateterritorydistrict-contacts (last visited 
Apr. 1, 2013) (outlining various state agencies charged with monitoring PDMPs).  
 126. Medical Marijuana Registry, VT. CRIM. INFO. CENTER. 
http://vcic.vermont.gov/marijuana_registry (last visited Apr. 8, 2013). 
 127. See Birnbaum et al., supra note 83, at 664 (providing that efforts to reduce prescription opioid 
abuse will require involvement from a variety of parties and agencies). 
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IV.  CONCLUSION 
In 2012, an election year, states continued to place proposed legislation for 
the medical use of marijuana on their ballots.128 Given the inevitable expansion of 
MML,129 it behooves policy-makers, prescribers, dispensers, and patients to 
understand the legacy of allowing increased use of marijuana for medical purposes. 
Such understanding requires careful evaluation of intended—and unintended—
consequences. In order to conduct meaningful evaluation, usable data should be 
collected at the national level. Such data would include marijuana utilization, 
reasons for utilization, and perceptions of risk of such use. National attention also 
should be given to the development of model standards of practice, based on 
evaluation of state MML, which could then better inform states contemplating 
MML, as well as improve the programs in states with existing MML. 
Meanwhile, individual states should consider implementing their own 
evaluations, considering both the medical utilization of marijuana, as well as the 
effects of MML on changes in recreational use (especially among youth), 
admissions to substance use treatment, impaired driving and consequences, changes 
in use of alternative therapies, and criminal activity.130 As well, states should 
consider implementing safeguards for medical marijuana expansion, including the 
use of patient medguides, registries, and other REMS-like components.131 
Expansion of legislation for medical marijuana can provide benefits, but can also 
involve risks. In order to best understand the tenuous balance of benefits and risks 
in MML, understanding and evaluating current programs should be made a top 
priority.  
 
 
 128. See Stephanie Condon, Marijuana, Same-Sex Marriage Initiatives Are Winners, CBS NEWS, 
Nov. 7, 2012, http://www.cbsnews.com/8301-250_162-57546156/marijuana-same-sex-marriage-
initiatives-are-winners (discussing the outcomes of proposed marijuana legislation in Colorado, 
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